• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

IntelGenx, Endo Ventures ink development and commercialization deal

December 28, 2016 By Sarah Faulkner

IntelGenx, Endo Ventures ink development and commercialization dealIntelGenx (OTCQX:IGXT) said today that it inked a development and commercialization deal with pharmaceutical company Endo Ventures. According to the agreement, the 2 companies will develop a new product using IntelGenx’s VersaFilm drug delivery technology to bring to the market in the U.S.

Endo will have certain exclusive rights to market and sell the product in the U.S. and pay IntelGenx in upfront payments and future milestone payments of undisclosed amounts. Both companies will share the profits made from commercializing the product.

Montreal-based IntelGenx reformulates approved drugs into oral thin films that are easier to take compared to capsules. The company reported that 40% of American adults have trouble swallowing pills. The VersaFilm is a thin, rapidly disintegrating film that bypasses first-pass metabolism and is easily administered to pediatric patients and patients who have a fear of choking or swallowing capsules.

“We are thrilled to further strengthen our partnership with such a significant global pharmaceutical organization as Endo,” president & CEO Dr. Horst Zerbe said in prepared remarks. “We see the completion of this deal as further validation of our VersaFilm technology and our ability to enter into high quality partnerships. IntelGenx continues to make tremendous progress in executing our strategy of becoming a global leader in pharmaceutical oral films.”

Filed Under: Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Endo Ventures Inc., IntelGenx

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS